FGFR1 and breast cancer: We demonstrate how CDGnet can be applied to a scenario where a patient with breast cancer has overexpression of both ESR1 and FGFR1, with the output representing the recommended therapies, the clinical context in which they are approved, and the links between the patient’s tumor molecular profile and the recommendations.